We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) was upgraded by equities research analysts at StockNews.com to a “sell” rating in a report released on Thursday. Several other brokerages also ...

According to TipRanks, Jones has an average return of -19.0% and a 21.33% success rate on recommended stocks. Corbus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Prelude Therapeutics (PRLD – Research Report) ...

Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at ...

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP rose 1.33% to $6.88 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index COMP ...

NORWOOD, Mass. (AP) — NORWOOD, Mass. (AP) — Corbus Pharmaceuticals Holdings Inc. (CRBP) on Tuesday reported a loss of $9.5 million in its fourth quarter. The Norwood, Massachusetts-based ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...